Announcement PDF 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Clinical and Commercial Update: Investor Webinar 2 October 2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to invite its shareholders and other supporters to a special webinar, showcasing clinical insights from Sexologist and Nurse Practitioner Melissa Had- ley Barrett and LTR Pharma Chief Medical Officer Professor Geoff Strange; together with a commercial update from LTR Pharma Executive Chair Lee Rodne. LTP is pioneering novel intranasal technology in AU and US, designed to treat erectile dysfunction (ED) in 10 minutes or less. This webinar will showcase: • Established clinical and real-world evidence proof points • Commercial momentum across LTR Pharma’s AU (SPONTAN®) and US (ROXUS®) products • Key upcoming catalysts and milestones LTR Pharma recently announced its final phase II report for SPONTAN which confirmed six-fold faster absorption (than oral vardenafil (p<0.0001), together with the completion of the FDA PK dataset. Register now to learn more during this webinar. Register Now: Clinical and Commercial Webinar • When: 10:00am – 11:00am AEDT • Presenters: Sexologist and Nurse Practitioner Melissa Hadley Barrett and LTR Pharma Chief Medical Of- ficer Professor Geoff Strange; together with a commercial update from LTR Pharma Executive Chair Lee Rodne. • Register now: https://us02web.zoom.us/webinar/register/WN_vxu6_6UXTVa87V3kuUd7aQ - ENDS - This announcement has been approved by the Chair. About LTR Pharma LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regu- latory pathways in the US and other key markets. LTR’s lead products, SPONTAN® and ROXUS® , are fast-acting intranasal sprays for the treatment of erectile dys- function, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW® , a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. LTR Pharma Investor Centre Stay informed with LTR Pharma’s latest announcements and market updates by visiting our Investor Centre or scan the QR code. For further information please contact: Media enquiries Investor enquiries Haley Chartres Peter McLennan haley@hackhq.com.au investors@ltrpharma.com